Search Results - "Tesei, S."

Refine Results
  1. 1

    Evaluation of LRRK2 G2019S penetrance : Relevance for genetic counseling in Parkinson disease by GOLDWURM, S, ZINI, M, MARIANI, L, TESEI, S, MICELI, R, SIRONI, F, CLEMENTI, M, BONIFATI, V, PEZZOLI, G

    Published in Neurology (03-04-2007)
    “…We report the results of a family-based study of LRRK2 G2019S penetrance in Parkinson disease. We studied 19 families identified through the analysis of…”
    Get full text
    Journal Article
  2. 2

    Zinc, metallothioneins and longevity: interrelationships with niacin and selenium by Mocchegiani, E, Malavolta, M, Muti, E, Costarelli, L, Cipriano, C, Piacenza, F, Tesei, S, Giacconi, R, Lattanzio, F

    Published in Current pharmaceutical design (01-09-2008)
    “…Ageing is an inevitable biological process with gradual and spontaneous biochemical and physiological changes and increased susceptibility to diseases. Some…”
    Get more information
    Journal Article
  3. 3
  4. 4

    647 A/C and +1245 MT1A polymorphisms in the susceptibility of diabetes mellitus and cardiovascular complications by Giacconi, R., Bonfigli, A.R., Testa, R., Sirolla, C., Cipriano, C., Marra, M., Muti, E., Malavolta, M., Costarelli, L., Piacenza, F., Tesei, S., Mocchegiani, E.

    Published in Molecular genetics and metabolism (01-05-2008)
    “…Diabetes mellitus is a chronic disease characterized by an overproduction of reactive oxygen species, which perturbs zinc metabolism and promotes the onset of…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    Zinc, metallothioneins and immunosenescence by Mocchegiani, E., Malavolta, M., Costarelli, L., Giacconi, R., Cipriano, C., Piacenza, F., Tesei, S., Basso, A., Pierpaoli, S., Lattanzio, F.

    Published in Proceedings of the Nutrition Society (01-08-2010)
    “…Ageing is an inevitable biological process with gradual and spontaneous biochemical and physiological changes and increased susceptibility to diseases. The…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    Hydrocarbon exposure and Parkinson's disease by PEZZOLI, G, CANESI, M, LEENDERS, K. L, ANTONINI, A, RIGHINI, A, PERBELLINI, L, BARICHELLA, M, MARIANI, C. B, TENCONI, F, TESEI, S, ZECCHINELLI, A

    Published in Neurology (12-09-2000)
    “…Single cases of parkinsonism have been associated with hydrocarbon solvents. To determine whether exposure to hydrocarbon solvents is related to PD. Cohort…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease by Zanettini, Renzo, Antonini, Angelo, Gatto, Gemma, Gentile, Rosa, Tesei, Silvana, Pezzoli, Gianni

    Published in The New England journal of medicine (04-01-2007)
    “…A cohort of patients with Parkinson's disease treated with either ergot-derived or non–ergot-derived dopamine agonists underwent echocardiographic evaluation…”
    Get full text
    Journal Article
  13. 13
  14. 14

    123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy by Antonini, A, Benti, R, De Notaris, R, Tesei, S, Zecchinelli, A, Sacilotto, G, Meucci, N, Canesi, M, Mariani, C, Pezzoli, G, Gerundini, P

    Published in Neurological sciences (01-10-2003)
    “…We used SPECT and the tracer (123)I-Ioflupane to measure dopamine transporter (DAT) binding in the caudate nucleus and the putamen of 70 patients with…”
    Get full text
    Journal Article
  15. 15

    Pramipexole versus sertraline in the treatment of depression in Parkinson's disease : A national multicenter parallel-group randomized study by BARONE, Paolo, SCARZELLA, Leonardo, MARCONI, Roberto, ANTONINI, Angelo, MORGANTE, Letterio, BRACCO, Fulvio, ZAPPIA, Mario, MUSCH, Bruno

    Published in Journal of neurology (01-05-2006)
    “…In addition to treating the motor symptoms of Parkinson's disease, the dopamine agonist pramipexole has shown an antidepressant effect. The trials, however,…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18

    Madopar HBS in fluctuating parkinsonian patients: two-year treatment by Pezzoli, G, Tesei, S, Ferrante, C, Cossutta, E, Zecchinelli, A, Scarlato, G

    Published in Movement disorders (1988)
    “…In an open-label study, we substituted conventional levodopa plus benserazide: 100/25 (Madopar) with a controlled-release form (HBS) in 18 fluctuating…”
    Get more information
    Journal Article
  19. 19

    Tolerability of paroxetine in Parkinson's disease: A prospective study by Tesei, Silvana, Antonini, Angelo, Canesi, Margherita, Zecchinelli, Anna, Mariani, Claudio B., Pezzoli, Gianni

    Published in Movement disorders (01-09-2000)
    “…Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are…”
    Get full text
    Journal Article
  20. 20